Association of fibrotic markers with diastolic function after STEMI

Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-08, Vol.14 (1), p.19122-11
Main Authors: Al Ali, Lawien, Meijers, Wouter C., Beldhuis, Iris E., Groot, Hilde E., Lipsic, Erik, van Veldhuisen, Dirk J., Voors, Adriaan A., van der Horst, Iwan C. C., de Boer, Rudolf A., van der Harst, Pim
Format: Article
Language:English
Subjects:
692/4019/592/75/2
692/4019/592/75/2/1674
692/53/2421
692/53/2422
Aged
Angioplasty
Biomarkers
Biomarkers - blood
Blood Proteins - metabolism
Cardiology
Cytokines
Diabetes
Diabetes mellitus
Diastole
Echocardiography
Ejection fraction
Female
Fibrosis
Follow-Up Studies
Galectin 3 - blood
Galectin-3
Galectins - blood
Heart attacks
Heart failure
Hospitalization
Humanities and Social Sciences
Humans
Interleukin-1 Receptor-Like 1 Protein - blood
Ischemia
Male
Middle Aged
multidisciplinary
Myocardial infarction
Patients
Plasma
Plasma levels
Prognosis
Science
Science (multidisciplinary)
ST Elevation Myocardial Infarction - blood
ST Elevation Myocardial Infarction - physiopathology
Tumorigenicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 ( P  = 0.75), and ST2 ( P  = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-69926-y